Nemolizumab MedChemExpress (MCE)

Product Name	Nemolizumab
Synonyms	Nemolizumab
CAS	1476039-58-3
EINECS
Chemical Formula
Molecular Weight
inchi
Package	1 mg;5 mg;10 mg
Price	Email to quote
Descriptions	Nemolizumab Nemolizumab MedChemExpress (MCE) HY-P99162 1476039-58-3 CIM331 99.70% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD). Nemolizumab (0.01-100 ng/mL, 2 d) inhibits the IL-31-dependent proliferation of Ba/F3 cells overexpressing hIL-31RA/cyIL-31RA and OSMR β[3]. Nemolizumab (0.01-100 ng/mL, 2 h pretreatment + 20 min co-incubation) inhibits hIL-31 (30 ng/mL)-induced STAT3 phosphorylation in A549 cells does dependently[3]. Nemolizumab (40-100 μg/kg, i.v., acute administration) blocks IL-31-induced scratching in cynomolgus monkeys[3]. Nemolizumab (1 mg/kg, s.c., acute administration) exerts a mean plasma concentration of 1490 ng/mL at Day 56 in 5 of 6 experiment cynomolgus monkeys and suppresses the scratching behaviour from shortly after administration until Day 56[3]. Humanized Human IgG2 kappa Human IgG2 kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Nakahara T, et, al. Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis. 2018 Descriptions Nemolizumab Nemolizumab MedChemExpress (MCE) HY-P99162 1476039-58-3 CIM331 99.70% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD). Nemolizumab (0.01-100 ng/mL, 2 d) inhibits the IL-31-dependent proliferation of Ba/F3 cells overexpressing hIL-31RA/cyIL-31RA and OSMR β[3]. Nemolizumab (0.01-100 ng/mL, 2 h pretreatment + 20 min co-incubation) inhibits hIL-31 (30 ng/mL)-induced STAT3 phosphorylation in A549 cells does dependently[3]. Nemolizumab (40-100 μg/kg, i.v., acute administration) blocks IL-31-induced scratching in cynomolgus monkeys[3]. Nemolizumab (1 mg/kg, s.c., acute administration) exerts a mean plasma concentration of 1490 ng/mL at Day 56 in 5 of 6 experiment cynomolgus monkeys and suppresses the scratching behaviour from shortly after administration until Day 56[3]. Humanized Human IgG2 kappa Human IgG2 kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Nakahara T, et, al. Nemolizumab and Atopic Dermatitis: the Interaction Between Interleukin-31 and Interleukin-31 Receptor as a Potential Therapeutic Target for Pruritus in Patients With Atopic Dermatitis. 2018 5:405–14. [2]. O Nemoto, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb 174(2):296-304. [Content Brief] [3]. Oyama S, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018 Jan 27(1):14-21. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-04-01 14:45:47

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-04-01 14:45:47

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-04-01 14:45:47

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-04-01 14:45:47

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-04-01 14:45:47

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-04-01 14:45:47

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-04-01 14:45:47

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact